Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 91

1.

ASSESSING SURROGATE ENDPOINTS IN VACCINE TRIALS WITH CASE-COHORT SAMPLING AND THE COX MODEL.

Qin L, Gilbert PB, Follmann D, Li D.

Ann Appl Stat. 2008 Mar;2(1):386-407.

PMID:
19079758
[PubMed]
Free PMC Article
2.

Evaluating candidate principal surrogate endpoints.

Gilbert PB, Hudgens MG.

Biometrics. 2008 Dec;64(4):1146-54. doi: 10.1111/j.1541-0420.2008.01014.x. Epub 2008 Mar 24.

PMID:
18363776
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Design and estimation for evaluating principal surrogate markers in vaccine trials.

Huang Y, Gilbert PB, Wolfson J.

Biometrics. 2013 Jun;69(2):301-9. doi: 10.1111/biom.12014. Epub 2013 Feb 14.

PMID:
23409839
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Evaluating a surrogate endpoint at three levels, with application to vaccine development.

Gilbert PB, Qin L, Self SG.

Stat Med. 2008 Oct 15;27(23):4758-78.

PMID:
17979212
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Sensitivity analysis for the assessment of causal vaccine effects on viral load in HIV vaccine trials.

Gilbert PB, Bosch RJ, Hudgens MG.

Biometrics. 2003 Sep;59(3):531-41.

PMID:
14601754
[PubMed - indexed for MEDLINE]
6.

Augmented designs to assess immune response in vaccine trials.

Follmann D.

Biometrics. 2006 Dec;62(4):1161-9.

PMID:
17156291
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Weighted likelihood method for grouped survival data in case-cohort studies with application to HIV vaccine trials.

Li Z, Gilbert P, Nan B.

Biometrics. 2008 Dec;64(4):1247-55. doi: 10.1111/j.1541-0420.2008.00998.x.

PMID:
19032178
[PubMed - indexed for MEDLINE]
8.

Commentary on "Principal stratification - a goal or a tool?" by Judea Pearl.

Gilbert PB, Hudgens MG, Wolfson J.

Int J Biostat. 2011;7(1):Article 36. doi: 10.2202/1557-4679.1341. Epub 2011 Sep 20.

PMID:
22049267
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Overview of the epidemiology methods and applications: strengths and limitations of observational study designs.

Colditz GA.

Crit Rev Food Sci Nutr. 2010;50 Suppl 1:10-2. doi: 10.1080/10408398.2010.526838.

PMID:
21132580
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Surrogacy assessment using principal stratification when surrogate and outcome measures are multivariate normal.

Conlon AS, Taylor JM, Elliott MR.

Biostatistics. 2014 Apr;15(2):266-83. doi: 10.1093/biostatistics/kxt051. Epub 2013 Nov 26.

PMID:
24285772
[PubMed - in process]
11.

Comparing biomarkers as principal surrogate endpoints.

Huang Y, Gilbert PB.

Biometrics. 2011 Dec;67(4):1442-51. doi: 10.1111/j.1541-0420.2011.01603.x. Epub 2011 Apr 22.

PMID:
21517791
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Statistical identifiability and the surrogate endpoint problem, with application to vaccine trials.

Wolfson J, Gilbert P.

Biometrics. 2010 Dec;66(4):1153-61. doi: 10.1111/j.1541-0420.2009.01380.x.

PMID:
20105158
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Accommodating missingness when assessing surrogacy via principal stratification.

Elliott MR, Li Y, Taylor JM.

Clin Trials. 2013;10(3):363-77. doi: 10.1177/1740774513479522. Epub 2013 Apr 3.

PMID:
23553326
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Sensitivity analyses comparing outcomes only existing in a subset selected post-randomization, conditional on covariates, with application to HIV vaccine trials.

Shepherd BE, Gilbert PB, Jemiai Y, Rotnitzky A.

Biometrics. 2006 Jun;62(2):332-42.

PMID:
16918897
[PubMed - indexed for MEDLINE]
15.

Evaluating principal surrogate endpoints with time-to-event data accounting for time-varying treatment efficacy.

Gabriel EE, Gilbert PB.

Biostatistics. 2014 Apr;15(2):251-65. doi: 10.1093/biostatistics/kxt055. Epub 2013 Dec 13.

PMID:
24337534
[PubMed - in process]
16.

A framework for assessing immunological correlates of protection in vaccine trials.

Qin L, Gilbert PB, Corey L, McElrath MJ, Self SG.

J Infect Dis. 2007 Nov 1;196(9):1304-12. Epub 2007 Oct 2.

PMID:
17922394
[PubMed - indexed for MEDLINE]
Free Article
17.

Informative value of Patient Reported Outcomes (PRO) in Health Technology Assessment (HTA).

Brettschneider C, L├╝hmann D, Raspe H.

GMS Health Technol Assess. 2011 Feb 2;7:Doc01. doi: 10.3205/hta000092.

PMID:
21468289
[PubMed]
Free PMC Article
18.

Surrogacy assessment using principal stratification and a Gaussian copula model.

Conlon A, Taylor J, Elliott M.

Stat Methods Med Res. 2014 Jun 19. pii: 0962280214539655. [Epub ahead of print]

PMID:
24947559
[PubMed - as supplied by publisher]
19.

Mark-specific hazard ratio model with multivariate continuous marks: an application to vaccine efficacy.

Juraska M, Gilbert PB.

Biometrics. 2013 Jun;69(2):328-37. doi: 10.1111/biom.12016. Epub 2013 Feb 19.

PMID:
23421613
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Influenza virus vaccine live intranasal--MedImmune vaccines: CAIV-T, influenza vaccine live intranasal.

[No authors listed]

Drugs R D. 2003;4(5):312-9. Review.

PMID:
12952502
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk